登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>NKp46 >NC1-H82F9

Biotinylated Human NKp46 / NCR1 / CD335 Protein, Fc,Avitag™, premium grade

热销产品推荐:

利用生物素-链霉亲和素系统的高特异性和高灵敏度的结合特性,可将生物素化蛋白与链霉亲和素相关产品联合应用于各类实验,与非生物素体系相比,检测速度更快、结合能力更强、非特异背景更低。

分子别名(Synonym)

NCR1,LY94,CD335,NK-p46,hNKp46

表达区间及表达系统(Source)

Biotinylated Human NKp46, Fc,Avitag, premium grade (NC1-H82F9) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - Asn 254 (Accession # O76036-1 ).

Predicted N-terminus: Gln 22

It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

Request for sequence

蛋白结构(Molecular Characterization)

NKp46 Structure

This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™)

The protein has a calculated MW of 54.5 kDa. The protein migrates as 55-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 0.01 EU per μg by the LAL method.

无菌(Sterility)

The sterility testing was performed by membrane filtration method.

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

NKp46 SDS-PAGE

Biotinylated Human NKp46, Fc,Avitag, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

NKp46 SEC-MALS

The purity of Biotinylated Human NKp46, Fc,Avitag, premium grade (Cat. No. NC1-H82F9) is more than 95% and the molecular weight of this protein is around 115-130 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

NKp46 ELISA

Immobilized Anti-NKP46 Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human NKp46, Fc,Avitag, premium grade (Cat. No. NC1-H82F9) with a linear range of 0.1-8 ng/mL (QC tested).

Protocol

 

背景(Background)

Natural cytotoxicity triggering receptor 1 (NCR1) is also known as Natural killer cell p46-related protein (NK-p46), Lymphocyte antigen 94 homolog (LY94), CD antigen CD335, which belongs to the natural cytotoxicity receptor (NCR) family. NCR1 contains two Ig-like (immunoglobulin-like) domains. NCR1 interacts with CD247 and FCER1G. NCR1 / CD335 may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
NKp46靶点信息
英文全称:Natural cytotoxicity triggering receptor 1
中文全称:
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:3详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定